Table 5 Glomerular and tubular histological characteristics after ex vivo pravastatin pre-treatment
| Â | Healthy + DMEM BMC recipients ( n = 5) | Healthy + pravastatin BMC recipients ( n = 5) | CKD + DMEM BMC recipients ( n = 10) | CKD + pravastatin BMC recipients ( n = 9) |
|---|---|---|---|---|
Glomerular | Â | Â | Â | Â |
 CD3 | 0.68 ± 0.34 | 0.72 ± 0.33 | 0.76 ± 0.19 | 0.67 ± 0.27 |
 ED-1 | 7.4 ± 1.0 | 5.0 ± 2.9 | 10.5 ± 5.5 | 7.9 ± 1.9 |
 Ki67 | 8.0 ± 0.76 | 6.4 ± 1.7 | 7.8 ± 1.8 | 7.8 ± 2.3 |
 TUNEL | 2.6 ± 1.3 | 2.1 ± 1.3 | 7.0 ± 4.6 | 4.4 ± 3.7 |
 γH2AX | 1.5 ± 1.6 | 0.6 ± 0.4 | 1.2 ± 0.8 | 1.4 ± 0.8 |
 GFP+ | 7.0 ± 6.6 | 2.5 ± 0.7 | 2.3 ± 1.9 | 5.2 ± 2.9 |
 JG12 | 42.5 ± 10 | 44.4 ± 9.9 | 42.8 ± 12.5 | 48.1 ± 9.0 |
Tubular | Â | Â | Â | Â |
 CD3 | 81 ± 11 | 96 ± 45 | 122 ± 59 | 98 ± 27 |
 TUNEL | 35 ± 24 | 65 ± 59 | 147 ± 116 | 95 ± 79 |
 γH2AX | 5.0 ± 1.6 | 4.3 ± 2.0 | 6.1 ± 2.8 | 5.3 ± 1.5 |
 GFP+ | 83 ± 82 | 31 ± 24 | 23 ± 20 | 50 ± 38 |